Agile Drug Development Required In A New Age Of Urgency

It’s time to reconsider the current paradigm of drug development, clinical trials and regulatory approvals.

Encouraging faster and agile drug development paradigms in dealing with aggressive global pandemics

In light of the current circumstances of a global pandemic, it’s time to reconsider the current paradigm of drug development, clinical trials and regulatory approvals.

The medical community, life sciences industry, health institutions, government, and regulatory bodies must act with a sense of urgency to examine any and all recommendations that bear a promise to delay or stop the spread of global pandemics.

Experts believe it’s time to ask some probing questions:

1. Are prevailing industry norms, processes, and regulations — largely unchanged for decades — adept and agile enough to deal with accelerating global pandemics such as COVID-19?
2. What aspects of drug development and regulatory approval need to be nuanced or should be fundamentally revisited in the face of increasing pandemics to ensure critically needed therapies?
3. How can we leverage modern digital sciences and technologies to accelerate development of new therapies in epidemics and pandemics, while also enabling the earliest possible access of promising, potentially lifesaving, new treatments to those afflicted?
4. Are there best practices of providing rapid access to novel treatments to patients in need during epidemics in other countries we can learn from?

In this eBook, three industry leaders, representing life sciences and technology, attempt to answer these questions and explore thoughtful and perhaps even provocative approaches to drug development.